Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.
BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increa...
| Автори: | , , , , , , , , , , , , , |
|---|---|
| Формат: | Journal article |
| Мова: | English |
| Опубліковано: |
Public Library of Science
2011
|
| _version_ | 1826303601843109888 |
|---|---|
| author | Tinsley, J Fairclough, R Storer, R Wilkes, F Potter, A Squire, SE Powell, D Cozzoli, A Capogrosso, R Lambert, A Wilson, F Wren, S De Luca, A Davies, K |
| author_facet | Tinsley, J Fairclough, R Storer, R Wilkes, F Potter, A Squire, SE Powell, D Cozzoli, A Capogrosso, R Lambert, A Wilson, F Wren, S De Luca, A Davies, K |
| author_sort | Tinsley, J |
| collection | OXFORD |
| description | BACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS: We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE: This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients. |
| first_indexed | 2024-03-07T06:05:12Z |
| format | Journal article |
| id | oxford-uuid:ed989d83-882f-490c-b5ff-d650858e7db3 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:05:12Z |
| publishDate | 2011 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:ed989d83-882f-490c-b5ff-d650858e7db32022-03-27T11:26:16ZDaily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:ed989d83-882f-490c-b5ff-d650858e7db3EnglishSymplectic Elements at OxfordPublic Library of Science2011Tinsley, JFairclough, RStorer, RWilkes, FPotter, ASquire, SEPowell, DCozzoli, ACapogrosso, RLambert, AWilson, FWren, SDe Luca, ADavies, KBACKGROUND: Duchenne muscular dystrophy (DMD) is a lethal, progressive muscle wasting disease caused by a loss of sarcolemmal bound dystrophin, which results in the death of the muscle fibers leading to the gradual depletion of skeletal muscle. There is significant evidence demonstrating that increasing levels of the dystrophin-related protein, utrophin, in mouse models results in sarcolemmal bound utrophin and prevents the muscular dystrophy pathology. The aim of this work was to develop a small molecule which increases the levels of utrophin in muscle and thus has therapeutic potential. METHODOLOGY AND PRINCIPAL FINDINGS: We describe the in vivo activity of SMT C1100; the first orally bioavailable small molecule utrophin upregulator. Once-a-day daily-dosing with SMT C1100 reduces a number of the pathological effects of dystrophin deficiency. Treatment results in reduced pathology, better muscle physiology leading to an increase in overall strength, and an ability to resist fatigue after forced exercise; a surrogate for the six minute walk test currently recommended as the pivotal outcome measure in human trials for DMD. CONCLUSIONS AND SIGNIFICANCE: This study demonstrates proof-of-principle for the use of in vitro screening methods in allowing identification of pharmacological agents for utrophin transcriptional upregulation. The best compound identified, SMT C1100, demonstrated significant disease modifying effects in DMD models. Our data warrant the full evaluation of this compound in clinical trials in DMD patients. |
| spellingShingle | Tinsley, J Fairclough, R Storer, R Wilkes, F Potter, A Squire, SE Powell, D Cozzoli, A Capogrosso, R Lambert, A Wilson, F Wren, S De Luca, A Davies, K Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_full | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_fullStr | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_full_unstemmed | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_short | Daily treatment with SMTC1100, a novel small molecule utrophin upregulator, dramatically reduces the dystrophic symptoms in the mdx mouse. |
| title_sort | daily treatment with smtc1100 a novel small molecule utrophin upregulator dramatically reduces the dystrophic symptoms in the mdx mouse |
| work_keys_str_mv | AT tinsleyj dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT faircloughr dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT storerr dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT wilkesf dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT pottera dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT squirese dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT powelld dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT cozzolia dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT capogrossor dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT lamberta dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT wilsonf dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT wrens dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT delucaa dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse AT daviesk dailytreatmentwithsmtc1100anovelsmallmoleculeutrophinupregulatordramaticallyreducesthedystrophicsymptomsinthemdxmouse |